865713-68-4

Basic information

• Product Name: ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
• CAS NO: 865713-68-4
• Molecular Weight: 281.742
• Mol File: 865713-68-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(865713-68-4)
• EPA Substance Registry System: ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(865713-68-4)

Safety Data

• Hazardous Substances Data: 865713-68-4(Hazardous Substances Data)

Upstream product

• 21633-77-2 diethyl 2-propionylmalonate 
• 105-53-3 diethyl malonate 
• 865713-63-9 diethyl 2-(1-chloropropylidene)malonate 
• 3528-58-3 5-Amino-1-ethylpyrazole 
• 1005418-87-0 diethyl {1-[(1-ethyl-1H-pyrazol-5-yl)amino]propylidene}propanedioate 
• 1005418-88-1 ethyl 1,6-diethyl-4-hydroxy-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 

Downstream Products

• 1179343-95-3 1,1-dimethylethyl 4-({5'-[({[6-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-2-pyridinyl]carbonyl}amino)methyl]-2'-fluoro-3-biphenylyl}methyl)-2-methyl-1-piperazinecarboxylate 
• 1179344-22-9 1,1-dimethylethyl (2S)-4-({5'-[({[2-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-5-pyridinyl]carbonyl}amino)methyl]-2'-fluoro-3-biphenylyl}methyl)-2-methyl-1-piperazinecarboxylate 
• 1179343-99-7 3-{[4-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}oxy)-1-piperidinyl]carbonyl}benzoic acid 
• 1179344-00-3 methyl 3-{[4-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}oxy)-1-piperidinyl]carbonyl}benzoate 
• 1179344-12-7 2-[(2-{[(3-bromo-4-fluorophenyl)methyl]amino}-2-oxoethyl)oxy]-N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}acetamide 
• 1179344-13-8 2-{[2-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-2-oxoethyl]oxy}-N-[(6-fluoro-3'-formyl-3-biphenylyl)methyl]acetamide 
• 1179344-21-8 6-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-N-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]-3-pyridinecarboxamide 
• 1179344-29-6 1,6-diethyl-N-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1179344-30-9 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1179344-52-5 2-{[2-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-2-oxoethyl]oxy}-N-({6-fluoro-3'-[(4-methyl-1-piperazinyl)methyl]-3-biphenylyl}methyl)acetamide 
• 1179344-53-6 2-({2-[({3'-[(4-acetylhexahydro-1H-1,4-diazepin-1-yl)methyl]-6-fluoro-3-biphenylyl}methyl)amino]-2-oxoethyl}oxy)-N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}acetamide 
• 1179344-54-7 2-{[2-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-2-oxoethyl]oxy}-N-({6-fluoro-3'-[(3-oxo-1-piperazinyl)methyl]-3-biphenylyl}methyl)acetamide 
• 1179344-55-8 2-{[2-({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)-2-oxoethyl]oxy}-N-({3'-{[[2-(dimethylamino)ethyl](methyl)amino]methyl}-6-fluoro-3-biphenylyl}methyl)acetamide 

Relevant articles and documents

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.